Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial

20252 citationsJournal Articlehybrid Open Access

Authors

Efficacy and safety analyses support deuruxolitinib as a treatment option in adults with AA.

Published in: Journal of the American Academy of Dermatology

Volume 94, Issue 4, pp. 1134-1143

Field-Weighted Citation Impact: 3.76